TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00873977

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP (REMstar (Respironics))
Description: Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP (REMstar (Respironics))
Description: Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
Study: NCT04066270

Intervention type: DIAGNOSTIC_TEST
Intervention: video nystagmography
Description: routine test battery applied to all cochlear implant candidates

Intervention type: DIAGNOSTIC_TEST
Intervention: video nystagmography
Description: routine test battery applied to all cochlear implant candidates
Study: NCT01048762

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise and dyspnoea counseling
Description: Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: home training
Description: one instruction in home based exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home training
Description: one instruction in home based exercise training
Study: NCT00326209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated Mesalamine Granules (eMG)
Description: eMG capsules will be administered per dose and schedule specified in the arm.
Study: NCT01278745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Study: NCT04608227

Intervention type: DEVICE
Intervention: Clearsight monitoring
Description: Non invasive hemodynamic monitoring using a finger cuff Cardiac ultrasound performed to calculate Velocity - Time - integral (VTI) Both intervention are performed before and after a passive leg raising challenge.
Study: NCT03121911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Description: Each exercise session will consist of:~1. warm up (10 minutes)- stretches and calisthenics exercises of low to moderate intensity;~2. interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold (VAT) found in CPET: Level 1 - 5 minutes in moderate intensity, at 80% of power reached in VAT; Levels 2 and 4 - 5 minutes of moderate to high intensity, at 100% of VAT; Levels 3 and 5 - 5 minutes of moderate to high intensity, 110% of VAT; Level 6 - 5 minutes in moderate intensity, at 70% of VAT.~3. cooling down (10 minutes) - stretching, and breathing exercises. An CPET will be performed every four weeks to adjust the intensity of training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Description: Each exercise session will consist of:~1. warm up (10 minutes)- stretches and calisthenics exercises of low to moderate intensity;~2. interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold (VAT) found in CPET: Level 1 - 5 minutes in moderate intensity, at 80% of power reached in VAT; Levels 2 and 4 - 5 minutes of moderate to high intensity, at 100% of VAT; Levels 3 and 5 - 5 minutes of moderate to high intensity, 110% of VAT; Level 6 - 5 minutes in moderate intensity, at 70% of VAT.~3. cooling down (10 minutes) - stretching, and breathing exercises. An CPET will be performed every four weeks to adjust the intensity of training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: The IMT session will take place just after the warm-up exercises and consist of 2 series of 12 inspirations with a 60% of Maximal Inspiratory Pressure (MIP) with the equipment POWERbreathe Plus Medic® (POWERbreathe International Ltd, Warwickshire, UK). The patient will be instructed to remain seated with a nasal clip during the IMT series to avoid nasal air leakage and will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minute interval between series. The training load will be adjusted weekly by a new evaluation of MIP to maintain the intensity of the exercise within the proposed value.~All the others exercises will be identical between group 1 and 2.
Study: NCT06215521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered orally
Study: NCT02371226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181 (HIRMAb-IDUA)
Description: intravenous infusion over 3-4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181 (HIRMAb-IDUA)
Description: intravenous infusion over 3-4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181 (HIRMAb-IDUA)
Description: intravenous infusion over 3-4 hours
Study: NCT01843842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: Safety and Efficiency of liquid dosage form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safety and Efficiency of liquid dosage form
Study: NCT03668886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal exercise program
Description: warm-up, strengthening exercise, aerobic exercise, cool-down
Study: NCT01239550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir
Description: Subjects randomized to insulin detemir treatment group will receive the basal insulin in a 3 mL. Flex Pen® containing 300 units of insulin. insulin detemir once daily administered with the evening meal (dinner) or at bedtime as add-on to their oral antihyperglycemia (see inclusion/exclusion criteria) meds throughout the 24 week treatment period. The goal of insulin therapy is to achieve near normoglycemia with a low rate of hypoglycaemic episodes.~Insulin injections will be given subcutaneously preferably in the thigh or abdomen.
Study: NCT00433914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB
Description: One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV
Description: One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
Study: NCT03639870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model iS3 three-stent trabecular micro-bypass system
Description: Provided in Arm/Group descriptions.
Study: NCT03914794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Participants will take Pemigatinib once daily on days 1 through 28 of each cycle prior to standard of care TURBT.
Study: NCT01886573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT01977599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Reminder for Breast Screening Appointment
Description: Non-clinical/administrative.
Study: NCT03257670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% Topical Lidocaine Gel
Description: This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2RE fractional laser therapy
Description: This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
Study: NCT03098849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko Breathing Technique
Description: Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
Study: NCT06466447

Intervention type: BEHAVIORAL
Intervention: Exposure and response prevention therapy
Description: Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by therapists remotely via video. The treatment was augmented by between-session text messaging.
Study: NCT04828070

Intervention type: OTHER
Intervention: Observation
Description: all participants followed for clinical data for one year, vital status check at 5 years
Study: NCT01169298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
Study: NCT02691975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
Study: NCT01118273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg
Description: Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium 440 mg (BAYH6689)
Description: Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg
Description: One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium 220 mg (BAYH6689)
Description: Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPH 50mg
Description: Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg / Diphenhydramine citrate 76 mg
Description: Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
Study: NCT03574675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.
Study: NCT00496730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin (+) ezetimibe
Description: simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: atorvastatin
Description: atorvastatin 10 mg; tablet, once daily, 8 Weeks
Study: NCT04383873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training by means of Armeo Spring device
Description: This patients group receive 40 experimental sessions. Each session is based on 30 min by using Armeo Spring device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current treatment based on conventional therapy
Description: All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current treatment based on conventional therapy
Description: All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional treatment based on conventional therapy
Description: This intevention was added for providing the same amount of therapy than those patients randomly enrolled in the intervention group. So, patients in the control group receive other 30 min of conventional therapy added on current treatment during 40 sessions.
Study: NCT00800436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
Study: NCT02004262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT02068742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: battery neuropsychological tests
Description: Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: battery neuropsychological tests
Description: Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
Study: NCT04240015

Intervention type: OTHER
Intervention: Oral-Dental Health-Related Quality of Life-United Kingdom (OHRQoL-UK) scale
Description: It consists of 4 different categories and 16 questions evaluating the effects of OHRQoL in positive and negative areas. These categories are as follows; symptoms (2 questions), physical status (5 questions), psychological status (5 questions), social status (4 questions) ' Questions on the OHRQoL-UK scale were scored using the Likert-type scale as 'very bad effect-score 1, bad effect-score 2, no effect-score 3, good effect-score 4, very good effect-score 5. The scores obtained from all questions were summed to give the scores of the 4 sub-categories separately and the total OHRQoL score. A higher total score indicates a higher OHRQoL.

Intervention type: OTHER
Intervention: Oral-Dental Health-Related Quality of Life-United Kingdom (OHRQoL-UK) scale
Description: It consists of 4 different categories and 16 questions evaluating the effects of OHRQoL in positive and negative areas. These categories are as follows; symptoms (2 questions), physical status (5 questions), psychological status (5 questions), social status (4 questions) ' Questions on the OHRQoL-UK scale were scored using the Likert-type scale as 'very bad effect-score 1, bad effect-score 2, no effect-score 3, good effect-score 4, very good effect-score 5. The scores obtained from all questions were summed to give the scores of the 4 sub-categories separately and the total OHRQoL score. A higher total score indicates a higher OHRQoL.
Study: NCT03076385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAL-506440
Description: Escalating dose levels

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00914251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin
Description: Administration of oral Hesperidin, 500 mg/daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of oral Placebo, 500 mg/daily
Study: NCT02263274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (TDCS)
Description: Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
Study: NCT02124239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate
Study: NCT02583906

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Description: Treatment with CPAP for six months in the CPAP arm.
Study: NCT03823066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coach Pepper
Description: Robot Peppers's height is 1.20 meters and it weighs 28 kilograms. Pepper will be called Coach Pepper, because it is connected, via web interfaces, with a theratainment app including cognitive and physical training
Study: NCT03478553

Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw

Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw

Intervention type: OTHER
Intervention: Questionnaire
Description: Pulmonary Fibrosis Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Pulmonary Fibrosis Questionnaire
Study: NCT00841802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 30mg once daily x 5 days
Study: NCT04086823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RZL-012
Description: Subcutaneous injection to the submental fat area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00625209

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebos
Description: placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone and fludrocortisone and placebo
Description: hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human activated protein C and placebos
Description: activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human activated protein C and hydrocortisone and fludrocortisone
Description: 96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
Study: NCT01515761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postero-lateral
Description: A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antero-Lateral
Description: A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
Study: NCT02970825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate to high intensity physical training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Low intensity physical activity and relaxation
Study: NCT03839173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human milk based human milk fortifier
Description: A human milk fortifier with added minerals made from donor human milk